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Protein kinases are involved in a wide variety of signal
transduction processes; their deregulation has been
implicated in a number of human diseases, including
cancer and disorders of the immune system. The recently
determined structures of two protein kinases, cAPK and
CDK2, in complex with an inhibitor, staurosporine, provide
a detailed account of inhibitor–kinase interactions and
inhibitor selectivity. 
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Introduction
The protein kinases constitute a large family of struc-
turally related enzymes that are responsible for the control
of a wide variety of signal transduction processes within
the cell [1]. Initial interest in protein kinases as pharmaco-
logical targets was stimulated by the findings that many
viral oncogenes encode structurally modified cellular protein
kinases with constitutive enzyme activity. These findings
pointed to the potential involvement of proto-oncogene-
encoded protein kinases in human proliferative disorders.
Subsequently, deregulated protein kinase activity, result-
ing from a variety of relatively subtle mechanisms, has
been implicated in the pathophysiology of a number of
important human diseases, including cancer [2] and
disorders of the immune system [3]. The development of
selective protein kinase inhibitors, which could block the
disease pathologies resulting from aberrant protein kinase
activity, has therefore generated much interest in the drug
discovery community. Such agents have the potential to
form a novel class of pharmacological agents with potential
benefits over existing clinical agents.
Protein kinase architecture
Since the structure of the catalytic subunit of cAMP-depen-
dent protein kinase (cAPK) was elucidated [4,5], approxi-
mately two dozen crystal structures of the catalytic domains
of protein kinases have been solved. The structural organi-
zation of this enzyme class is now well established [6].
These proteins have a structurally conserved catalytic unit,
comprising two major domains that are further subdivided
into eleven subdomains ([7]; see Figure 1a of [8]). The
N-terminal portion forms a small lobe, the architecture of
which is generally composed of an antiparallel five-stranded
b sheet and one a helix, whereas the lower C-terminal
domain contains mostly a -helical architecture. These two
domains are connected by a single peptide strand, to
which the adenine moiety of ATP binds via an eleven-
membered hydrogen-bond cycle, involving the N1 and
N6 amino group, and the backbone carbonyl and NH
functions of two nonconsecutive residues. This linker acts
as a hinge about which the domains can rotate with
respect to each other, without disruption of the secondary
structure of the kinase [9]. Several changes to torsion
angles in the linker backbone allow these movements to
occur. The ribose group of ATP is anchored to the
enzyme via hydrogen bonds with residues within the
ribose-binding pocket. The triphosphosphate group is held
via two metal coordinate-covalent bonds to aspartate and
asparagine residues on the DFG motif and the catalytic
loop, respectively. In addition, polar interactions with
several residues from the glycine-rich loop, the conserved
DFG motive and the catalytic loop further stabilize the
phosphates and the transition state generated during the
phosphotransfer reaction. 
ATP competitive inhibitors
The structures of a number of protein kinases in complex
with ATP, or analogues, have now been solved which
reveal the structural basis for nucleotide binding. It was
initially suggested that the ATP-binding cleft of this
enzyme class would not prove to be a good target for drug
discovery, due to the fact that all members of the family
must bind the same nucleotide co-factor. Empirical
screening of compound libraries has identified a number
of ATP competitive inhibitors, some of which show a high
degree of selectivity within the kinase family, however
[10,11]. One of the first kinase inhibitors discovered was
staurosporine [12], a microbial alkaloid with high potency
but little selectivity. Since its inhibitory activity against
protein kinase C was reported in 1986 [13], the structure
of staurosporine has been the focus of intense medicinal
chemistry interest; hundreds of derivatives based on this
structure have been produced, some of which demonstrate
selective kinase inhibition. A major obstacle in the design
of more selective analogues of this type has been the diffi-
culty in deconvoluting the complex structure–activity rela-
tionship (SAR) data, generated against multiple protein
kinase targets. The simultaneous arrival of structural data
from two protein Ser/Thr kinases in complex with stau-
rosporine [8,14] should now enable the retrospective
analysis of this SAR data and its application to structure-
based drug design.
Binding mode of staurosporine
The structural basis for the inhibitory mechanism of
staurosporine has been a matter of debate due to conflict-
ing kinetic data [15,16]. In an attempt to understand the
binding mode of staurosporine and related derivatives,
Furet et al. [17] have modeled staurosporine within the
nucleotide-binding cleft of the cAPK. In this model, the
lactam moiety of staurosporine reproduces the hydrogen-
bonding interactions of the adenine ring with the back-
bone of the enzyme linker. The indolylcarbazole ring
system is coplanar with the adenine moiety, and the sugar
moiety overlaps the ribose of ATP. The tetrahydropyran
ring was modeled in the boat conformation with its methy-
lamine group protonated. The boat conformation of the
glycosyl group, observed in the crystal structure of stau-
rosporine methyl iodide [18], was believed to be the
biologically active form. This trimethyl ammonium deriv-
ative, a cationic analogue of staurosporine, which due to
severe steric interactions between the trimethyl ammo-
nium group and the extended indolocarbazole ring cannot
adopt a chair conformation, retains high potency towards
many kinases. 
The crystal structure of staurosporine in complex with
cAPK and an inhibitor peptide, PKI(5–24), described by
Prade et al. in this issue of Structure, confirms this model
and offers atomic resolution details of the intermolecular
interactions between this alkaloid and the enzyme
substrate-binding cleft [14]. Another recently published
report [8] describes the structure of staurosporine in
complex with cyclin-dependent kinase 2 (CDK2). These
two complexes suggest an intriguing degree of enzyme
flexibility (relative to their ATP-bound conformations
[19–21]). 
Staurosporine bound to the cAPK 
The crystal structure of the catalytic domain of bovine
recombinant cAPK in complex with staurosporine and
PKI(5–24) reveals the binding mode of this alkaloid
within the ATP-binding cleft. In an interesting contrast to
the crystal structures of cAPK in ternary complexes (with
MgATP.PKI [20], MnAMP–PNP.PKI [19] and isoquino-
line sulfonamides.PKI [22]), which are all in the closed
conformation, a 13° opening of the cleft is observed in the
recently determined structure of cAPK in a ternary
complex with staurosporine and PKI (see Figure 7 and
Figure 8 in [14]). In this structure, the staurosporine
molecule, as predicted by the modeling study of Furet et
al. [17], occupies a site which overlaps with that of the
adenosine moiety of ATP. The lactam ring mimics the
amino pyrimidine ring of adenine in its hydrogen bonding
interactions with the backbone carbonyl group of Glu121
and the amide NH group of Val123 in the linker region.
Superimposition of the structurally conserved C-terminal
domain of the cAPK–staurosporine structure onto that of
the MnAMP–PNP.PKI ternary complex [19] revealed a
12° difference, between the two structures, in the orienta-
tion of the molecular plane of staurosporine relative to that
of adenine. The glycosyl moiety of staurosporine is in the
boat conformation. It appears that the N-methylamine
group is protonated, because hydrogen bonding from this
group to the sidechain of Glu127 and mainchain carbonyl
of Glu170 is observed.
The highly hydrophobic surface of the staurosporine
nucleus is complemented by the large hydrophobic
surface of the ATP-binding cleft, such that staurosporine
binds to cAPK making many favorable contacts: Leu49,
Phe54, Val57, Ala70, Lys72, Val104, Met120, Tyr122,
Glu127 and Phe327, which surround staurosporine, make
many favorable van der Waal contacts. The positions of
nearly all residues that interact with staurosporine are
altered with respect to their positions in the ternary
complex [19]. These changes are required to accom-
modate staurosporine, which is significantly larger than
ATP. The most dramatic changes involve the following
residues (Figure 1): Thr183, which hydrogen bonds to N7
of ATP but makes no equivalent interaction with stau-
rosporine, Met120 in the linker region and Phe327 on the
C-terminal tail. Phe327 is displaced away from the binding
cleft and its phenyl group is rotated to make a favorable
perpendicular aromatic–aromatic interaction with one of
the indole aryl rings of staurosporine. This change causes
an overall displacement of the C-terminal tail in the vicin-
ity of Phe327. In contrast, Phe54 in the glycine-rich loop
rotates inwards towards the staurosporine molecule and
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Figure 1
Binding of staurosporine to cAPK. Residues within a 4 Å radius of the
staurosporine nucleus are displayed. The labeled residues (cyan) are
those which display the most pronounced sidechain conformational
changes and are discussed in the text. (For more details, please see
figures in [14].)
Minireview  Protein kinase–inhibitor complexes Toledo and Lydon    1553
blocks its solvent accessibility. In the modeling study of
Furet et al. [17], displacements of the sidechains of
Phe327 and Thr183 were necessary for the docking of
staurosporine, due to encountered steric constrains. As the
conformation of Phe54 did not cause any steric hindrance,
its movement was not previously predicted.
Staurosporine bound to CDK2 
In the report from the group of Louise Johnson [8], the
crystal structure of staurosporine in a binary complex with
CDK2, a cell-cycle kinase, provides complementary evi-
dence for the binding mode of this inhibitor and provides
additional information on the origins of selectivity of related
compounds. In this complex (Figure 2), the position and
conformation of staurosporine in the ATP-binding cleft are
virtually identical to that observed in the cAPK complex
(see also Figures in [8]). The corresponding hydrogen-
bonding interactions of the lactam moiety with backbone
amino acids Glu81 and Leu83 in the linker region and those
in the ribose-binding pocket are reproduced. Upon binding
to CDK2, staurosporine causes a slight opening of the ATP-
binding cleft, in contrast to the closing observed in the
ATP-bound form of CDK2 [21]. Several residues in the
area of the DFG motif move in order to accommodate the
large staurosporine molecule. The other major con-
formational change involves the sidechain of Gln131, which
moves to avoid a possible steric clash with staurosporine.
The sidechain of His84 in the hinge region also moves,
perhaps as a result of the opening of the cleft. Dis-
placement of the sidechain of His84 has been observed
previously in complexes of CDK2 with the inhibitors Olo-
moucine [23] and Roscovitine [24]. The sidechain of Tyr15
on the glycine-rich loop, which is equivalent to Phe54 in
cAPK, is not reported to undergo large conformational
motions as observed in the cAPK–staurosporine structure.
Perhaps Tyr15 is involved in hydrogen-bonding interac-
tions which prevent occurrence of this movement. 
Figure 2
Binding of staurosporine to CDK2. Residues within a 4 Å radius of the
staurosporine nucleus are displayed. The labeled residues (cyan) are
those which display the most pronounced sidechain conformational
changes and are discussed in the text. (For more details, please see
figures in [8].)
Figure 3
Structural comparisons of the catalytic
domain architectures of the cAMP-dependent
and CDK2 Ser/Thr kinases. (a) The c-APK
structure from [20], with N- and C-terminal
extensions in red, PKI(5–24) in green and
ATP in blue. (b) CDK2 from [23], with ATP
placed in the ATP-binding site and C domain
insert in red.
The C-terminal tail, which contains Phe327 in cAPK, is
not present in CDK2, leaving this region of the ATP-
binding cleft accessible to solvent. Figure 3 highlights
the major structural differences between the catalytic
domains of these two Ser/Thr protein kinases. Interest-
ingly, in the crystal structures of CDK2 in complex with
Olomoucine [23] and Roscovitine [24], the benzyl group
common to both inhibitors protrudes out the cleft via the
free space made by the absence of the C-terminal tail.
These structural features suggest differences that can be
exploited for drug design.
Origin of potency and selectivity of staurosporine and its
derivatives
Staurosporine is a large highly hydrophobic molecule. The
cleft at the domain interface is also highly hydrophobic,
such that large complementary surface areas surround the
bisindolylcarbazole ring system of bound staurosporine. As
observed in both crystal structures [8,14], and in the Furet
model [17], staurosporine overlaps well with the adeno-
sine group of ATP. The lactam ring mimics the hydrogen-
bonding interactions of adenine, while the glycosyl group
mimics those of ribose. The more polar region of the cleft,
where catalysis occurs, is not occupied by this alkaloid.
Although reduction of the carbonyl or substitution at the
NH of the lactam group render staurosporine inactive,
structural changes in the glycon area generally have less
effect on potency [25]. Compounds such as Arcyriaflavin A
[26], which lacks a glycosyl group; K-252a [25], with a dif-
ferent sugar ring, and the cationic trimethylamine deriva-
tive of staurosporine [18], which cannot form hydrogen
bonds to the sugar pocket of the kinase, have similar
potencies. Thus, the potency of staurosporine must be a
1554 Structure 1997, Vol 5 No 12
Figure 5
Structural comparisons of (a) staurosporine,
(b) staurosporine aglycon, (c) bisindolyl-
maleimide and (d) dianilinophthalimide. The
conformations shown were generated by
molecular mechanics (MM2 as implemented
within the Sybyl), on the basis of the
conformations of the corresponding crystal
structures. Atoms are shown as: carbon,
yellow; hydrogen, cyan; oxygen, red; and
nitrogen, blue.
Figure 4
Superimposition of staurosporine (red) onto ATP (cyan), from the
structure of it hydrogen bonded to the backbone of cAPK.
result of the interplay between the hydrogen-bond anchor-
ing to the linker region and the large number of favorable
hydrophobic contacts with the enzyme. Both groups [8,14]
discuss the potency of staurosporine on the basis of the
total surface area (inhibitor plus enzyme) buried by the
binding interactions. The importance of the complemen-
tarity of the interacting surfaces of the inhibitor and
enzyme (of hydrophobic and electrostatic nature) are
clearly illustrated by these new structures.
As staurosporine overlaps well with the adenosine portion
of ATP (Figure 4), it is not surprising that it acts as a
nonselective protein kinase inhibitor. Several compound
classes related to staurosporine, however, show a high
degree of selectivity within the protein kinase family. For
example, the diindolylmaleimides [27] show selectivity
for Ser/Thr protein kinase C, whereas the structurally
related dianilinophthalamides [28] are selective towards
the EGF-R tyrosine protein kinase. The origin of
selectivity of these compounds can be attributed to dif-
ferences in molecular shapes resulting form alternative
cleavage of the indolylcarbazole ring system (Figures 5
and 6). Staurosporine and staurosporine aglycon, which
have flat planar ring systems, are different in terms of
three-dimensional conformation and structure from di-
indolylmaleimide [26] and dianilinophthalamide [27], as
revealed by their crystal structures. These differences
probably contribute to the observed selectivity profiles.
Structure-based drug design of selective inhibitors
Staurosporine and related structures such as diindolyl-
maleimides, staurosporines aglycon and dianilinophthala-
mides, have been extensively derivatized with the
objective of obtaining selectivity towards pharma-
cologically interesting targets. A major challenge in this
task has been the deconvolution of the complex body of
SAR data, generated against a number of protein kinase
targets. The simultaneous publications of structural data
from two different protein kinases in complex with stau-
rosporine should greatly facilitate this process. Addi-
tionally, the previously published crystals structures of
CDK2 in complex with the inhibitors Olomoucine [23],
Roscovitine [24] and flavonoid L868276 [29], and cAPK
in complex with isoquinolinesulfonamide derivatives
(H-7, H-9 and H-89) [22] should also allow the structure-
based exploitation of these pharmacophores in novel
ways. With respect to CDKs (e.g. CDK2 and CDK4), this
knowledge should have immediate applications in the
area of oncology.
The accuracy of the predictions made by Furet et al. rein-
forces the potential value of modeling as a medicinal
chemistry tool. The utility of such modeling methods for
structure-based drug design is increasing with the avail-
ability of multiple protein kinase structures. Due to the
sequence and structural homology within the protein
kinase family, useful models can be constructed for
pharmacological targets that have so far eluded structure
determination. This is well illustrated by the generation of
a model of the EGF-R protein kinase, based on the cAPK
structure [20]. This model has been successfully utilized
to guide medicinal chemistry programs that have resulted
in the highly potent and selective phenylaminopyrrolo-
pyrimidines [30] and pyrazolopyrimodines [31] classes of
inhibitors.
Conclusion
The two structures reviewed here greatly contribute to
the understanding of structure–activity relationships and
the origin of selectivity of several classes of compounds
believed to be structurally related to staurosporine. This
knowledge should greatly assist medicinal chemistry
strategies for modification of existing leads and for future
de novo design. One interesting lesson learned from these
papers is the degree of flexibility of the kinase architec-
ture, not in the well-appreciated sense of domain rotation,
but in the subtle adjustment of specific residue positions
to make room for a bulky ligand. Structure-based design
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Figure 6
Superimposition of the structures of staurosporine (red), staurosporine
aglycon (blue), dianilinophthalimide (yellow) and bisindolylmaleimide
(green). Structures are viewed from (a) edge on and (b) front.
strategies that fail to take into account this flexibility will
probably result in lost opportunities. After all, the dynamic
nature of the interactions and the multiple tasks (both cat-
alytic and regulatory) carried out by these enzymes is sug-
gestive of this inherent flexibility. 
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